Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666991 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 study of Peritoneal Neoplasms, sponsored by CritiTech.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT00666991: Completed Phase 1 study of Peritoneal Neoplasms, sponsored by CritiTech.
NCT00666991 is a Phase 1 study of Peritoneal Neoplasms that has completed, run by CritiTech. The registered enrollment target is 22 participants, below the 436-participant average among 14 other Peritoneal Neoplasms trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666991, a Phase 1 study of Peritoneal Neoplasms, has completed, sponsored by CritiTech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity.
Conditions Studied
Interventions
- DRUG nanoparticulate paclitaxel
Study Locations (3)
Kansas
- University of Kansas Medical Center - Kansas City
- Cancer Center of Kansas - Wichita
Oklahoma
- Peggy and Charles Stephenson Oklahoma Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
What the finished NCT00666991 record still lists
NCT00666991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 436-participant average among 14 other Peritoneal Neoplasms trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Peritoneal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which nanoparticulate paclitaxel is the first listed.
NCT00666991 reports a single indexed study location in Kansas, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00666991 about?
NCT00666991 is a clinical study titled "Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers". The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity.
What is the current status of trial NCT00666991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-07. Estimated completion is 2013-05.
What conditions does trial NCT00666991 study?
This clinical trial studies the following conditions: Peritoneal Neoplasms.
What interventions are being tested in trial NCT00666991?
The interventions under investigation include: nanoparticulate paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00666991?
This trial is sponsored by CritiTech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666991 being conducted?
This trial has 3 study locations across Kansas, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00666991's enrollment target sits among peer trials
22 13th of 14 higher than 2 of 14 other Peritoneal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peritoneal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
RECRUITING · Phase 3
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia